ICU Medical (NASDAQ: ICUI) reported Q4 EPS of $2.07, $0.27 better than the analyst estimate of $1.80. Revenue for the quarter came in at $340.4 million versus the consensus estimate of $315.77 million.

• Fourth quarter 2018 revenue was $340.4 million, compared to $370.1 million in the same period last year.
• GAAP gross profit for the fourth quarter of 2018 was $134.6 million, as compared to $137.5 million in the same period last year.
• GAAP gross margin for the fourth quarter of 2018 was 40%, as compared to 37% in the same period last year.
• GAAP net loss for the fourth quarter of 2018 was $7.4 million, or $0.36 loss per diluted share, as compared to GAAP net income of $49.7 million, or $2.33 per diluted share, for the fourth quarter of 2017.
• Adjusted diluted earnings per share for the fourth quarter of 2018 were $2.07 as compared to $2.98 for the fourth quarter of 2017.
• Also, adjusted EBITDA was $69.3 million for the fourth quarter of 2018 as compared to $70.1 million for the fourth quarter of 2017.

Vivek Jain, ICU Medical's Chief Executive Officer, said, "Fourth quarter revenues, adjusted EBITDA and adjusted diluted earnings per share were in line with our expectations.”

GUIDANCE:

ICU Medical sees FY2019 EPS of $9.00-$9.90, versus the consensus of $9.40.

For earnings history and earnings-related data on ICU Medical (ICUI) click here.